Inhibitor Therapeutics, Inc.
INTI · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2 | $1 | $0 | $0 |
| G&A Expenses | $2 | $2 | $1 | $0 |
| SG&A Expenses | $2 | $2 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $3 | $1 | $0 |
| Operating Income | -$4 | -$3 | -$1 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $13 | $0 |
| Pre-Tax Income | -$3 | -$3 | $12 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$3 | $12 | -$0 |
| % Margin | – | – | – | – |
| EPS | -0.019 | -0.02 | 0.033 | -0.001 |
| % Growth | 3% | -161.5% | 2,600% | – |
| EPS Diluted | -0.019 | -0.018 | 0.03 | -0.001 |
| Weighted Avg Shares Out | 172 | 151 | 366 | 376 |
| Weighted Avg Shares Out Dil | 172 | 172 | 368 | 376 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $3 | $1 | $0 |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | – |